The oral SYK inhibitor (SYKi) fostamatinib had reached a phase II clinical study that recruited 68 R/R DLBCL patients; albeit, while the drug was generally well tolerated, its efficacy at the applied doses and schedule was poor (Table 3). This evidence concerns the gene SYK and diffuse large B-cell lymphoma.